EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial

Uday C Ghoshal iD, B S Ramakrishna, Pravin M Rathi, Akash Shukla iD, Manas Kumar Panigrahi, Shubham Jain iD, Indraneel Saha, Karmabir Chakravartty, Madhuri Singh, Uzma Mustafa, Shikha Sahu, Ujjala Ghoshal und 3 weitere

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70137 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Uday C Ghoshal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Hauptthemen laut MEDLINE: Probiotics, Irritable Bowel Syndrome, Lactobacillus acidophilus, Bifidobacterium animalis. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Zydus Healthcare Limited and Shanti Public Educational and Development Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As dysregulated gut microbiota is known in irritable bowel syndrome (IBS) and probiotics may improve it, we investigated the efficacy and safety of a combination probiotic, Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. lactis BB‐12 in non‐constipated IBS.

Methods

Two hundred non‐constipated IBS patients were randomized to the above‐mentioned probiotic and placebo for 84 days. The outcome measures included IBS–Global Improvement Scale (IBS‐GIS), IBS–Quality of Life (IBS‐QoL), EAR3Q, IBS–Severity Scoring System (IBS‐SSS), and patient‐reported improvement. Fecal microbiota was evaluated in a subset.

Results

Response in IBS‐GIS was higher with probiotics than with placebo at days 28 (19.3% vs. 8.9%; p = 0.048), 56, and 84. Total and abdominal pain, distension, and QoL scores of IBS‐SSS decreased at day 28 with probiotics that persisted till days 56 and 84. The percentage of patients with “severe” symptoms reduced from 20.8% at baseline to 3.9% at day 84, and the median IBS‐QoL score decreased significantly at day 28; the beneficial effect on QoL was sustained till days 56 and 84 ( p < 0.001). Improvement in abdominal pain, distension, urgency of defecation, bowel habit satisfaction, and stool frequency was noted earlier with probiotics than with placebo; 4.0% in the probiotic group and 0.9% in the placebo group had mild/moderate adverse events ( p = 0.167). Symptom recurrence occurred in 3.0% in the probiotic group and 3.9% in the placebo group during follow‐up of 180 days ( p = 0.718). No difference was observed in the fecal microbiota between the two groups, but healthy genera were enriched with probiotics.

Conclusions

The probiotic blend studied was more effective than placebo in non‐constipated IBS in adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsIrritable Bowel SyndromeLactobacillus acidophilusBifidobacterium animalisHumansDouble-Blind MethodFemaleMaleAdultMiddle AgedTreatment OutcomeQuality of LifeGastrointestinal MicrobiomeFecesSeverity of Illness Index

Stichwörter der Autor:innen

Disorders of gut–brain interactionIBS–Symptom Severity Scalefunctional bowel disordergut microbiotasmall intestinal bacterial overgrowth

Autor:innen und Institutionen

  • Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
  • Institute of Gastrosciences & Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata, India.
  • Department of Gastroenterology, SRM Institutes of Medical Sciences (SIMS Hospital), Chennai, India.
  • Department of Gastroenterology, Topiwala National Medical College & BYL Nair Charitable Hospital, Mumbai, India.
  • Department of Gastroenterology, Seth G S Medical College and KEM Hospital, Mumbai, India.
  • Department of Gastroenterology, All India Institute of Medical Science, Bhubaneswar, India.

ORCID-Profile: Uday C Ghoshal, Akash Shukla, Shubham Jain, Sanjay Chandnani, Mahesh K Goenka

Förderung

  • Zydus Healthcare Limited and Shanti Public Educational and Development Society

Zitieren

APA

Ghoshal, U. C., Ramakrishna, B. S., Rathi, P. M., Shukla, A., Panigrahi, M. K., Jain, S., Saha, I., Chakravartty, K., Singh, M., Mustafa, U., Sahu, S., Ghoshal, U., Chandnani, S., Goenka, M. K., & Mitra, M. (2026). Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70137

Vancouver

Ghoshal UC, Ramakrishna BS, Rathi PM, Shukla A, Panigrahi MK, Jain S, et al. Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70137

BibTeX
@article{Ghoshal2026,
  author = {Ghoshal, Uday C and Ramakrishna, B S and Rathi, Pravin M and Shukla, Akash and Panigrahi, Manas Kumar and Jain, Shubham and Saha, Indraneel and Chakravartty, Karmabir and Singh, Madhuri and Mustafa, Uzma and Sahu, Shikha and Ghoshal, Ujjala and Chandnani, Sanjay and Goenka, Mahesh K and Mitra, Monjori},
  title = {Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70137}
}
Kostenlos starten →